Watch for updates on the four ongoing Phase 3 trials (ROSETTA Lung-01, -02, -201, -202) and potential regulatory filings in second-line NSCLC. The consistent activity across PD-L1 levels and histologies strengthens the case for pumitamig as a broad lung cancer therapy.
Price Chart
Executive Summary
BioNTech and BMS reported first Phase 2 data from the ROSETTA Lung-107 trial showing pumitamig plus docetaxel achieved a 36.7% confirmed objective response rate and 6.9-month median progression-free survival in second-line metastatic NSCLC after immunotherapy plus chemotherapy, versus ~3.6-3.9 months historical PFS for docetaxel alone. The data support pumitamig's potential in a high-unmet-need setting and add to three global Phase 2 datasets in lung cancer, with four ongoing Phase 3 trials.
Key Facts
- Confirmed ORR of 36.7% and disease control rate of 90.0% in 30 efficacy-evaluable patients with metastatic NSCLC after progression on immunotherapy plus chemotherapy
- Median PFS of 6.9 months (95% CI: 4.2 – not reached) vs historical ~3.6-3.9 months for docetaxel alone
- Responses observed across PD-L1 expression levels (cORR: 42.9% TPS <1%, 33.3% TPS 1-49%, 40.0% TPS ≥50%) and histologies (57.1% squamous, 30.4% non-squamous)
- Manageable safety profile: grade ≥3 TRAEs in 18.0%, no pumitamig-related deaths or DLTs
- Third global Phase 2 dataset for pumitamig in lung cancer; four ongoing global Phase 3 trials with registrational potential
Financial Impact
No financial figures disclosed; pumitamig is investigational with no approved product or revenue. The data de-risks a potential second-line NSCLC indication, which could expand the addressable market for pumitamig if approved.
Risk Factors
- Phase 2 data are from a single-arm, open-label trial with small sample size (n=50); confirmatory Phase 3 data are needed
- Competition from existing PD-(L)1xVEGF bispecifics and other checkpoint inhibitor combinations in second-line NSCLC
- Regulatory approval is not guaranteed; safety and efficacy must be confirmed in larger randomized trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387717 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $86.00 | awaiting T+60 | — | $86.86 (+1.00%) |
Oct 26, 2026 today | 6-K | $84.52 | awaiting T+60 | — | $86.86 (−2.77%) |
Oct 26, 2026 today | Press Release | $88.41 | awaiting T+60 | — | $86.86 (+1.75%) |
Oct 25, 2026 1d ago | Press Release | $88.40 | awaiting T+60 | — | $86.86 (−1.74%) |
Oct 22, 2026 4d ago | 6-K | $89.67 | awaiting T+60 | — | $86.86 (−3.13%) |
Oct 19, 2026 7d ago | 6-K | $89.21 | awaiting T+60 | — | $86.86 (−2.63%) |
Oct 19, 2026 7d ago | Press Release | $89.21 | awaiting T+60 | — | $86.86 (−2.63%) |
Oct 13, 2026 13d ago | 6-K | $88.66 | awaiting T+60 | — | $86.86 (+2.03%) |
Sep 14, 2026 6w ago | 6-K | $98.86 | awaiting T+60 | — | $86.86 (−12.14%) |
Sep 14, 2026 6w ago | Press Release | $98.86 | awaiting T+60 | — | $86.86 (−12.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers